---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266974"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:14:58.150642+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q3 revenue $94M (+102% YoY); MRD profitable, guidance raised

## Summary
- Revenue $94.0M (up 102% YoY) includes $33.7M from full amortization of Genentech payment.
- MRD revenue $56.8M (+52% YoY); MRD achieved profitability and cash flow positivity with Adj. EBITDA $7.0M.
- clonoSEQ test volume 27,111 (+38% YoY); NCCN guidelines updated for CLL MRD-guided treatment duration.
- Net income $9.5M vs $32.1M loss in Q3 2024; Adj. EBITDA $28.0M vs $14.3M loss.
- FY2025 MRD revenue guidance raised to $202-207M; total operating spend and cash burn guidance reduced.

## SEC filing metadata
- accession: 0001193125-25-266974
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000119312525266974/0001193125-25-266974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000119312525266974/adpt-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266974
- JSON: https://secwatch.observer/filing/0001193125-25-266974.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.